In contrast, we observed a significant decrease in IL5, IL10, IL13, and IL6 levels, which are typically associated with tumor-promoting type 2 immune responses, which are known to support tumor growth, metastatic dissemination, and tumor evasion of immune surveillance. The gene discussed is IL6; the disease is neoplasm.